Clinical Trial Update: Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BEMA Buprenorphine NX for induction in opioid-dependent subjects has been withdrawn. The study did not proceed to completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Dependence

Drugs mentioned

• BEMA Buprenorphine NX (buprenorphine)

Snippet

Sponsor: BioDelivery Sciences International | Conditions: Opioid Dependence | Phase 3 | Status: WITHDRAWN